These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 27640138)
21. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653 [TBL] [Abstract][Full Text] [Related]
22. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy. Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J PLoS One; 2016; 11(11):e0166194. PubMed ID: 27835689 [TBL] [Abstract][Full Text] [Related]
23. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study. Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939 [TBL] [Abstract][Full Text] [Related]
24. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma. Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025 [TBL] [Abstract][Full Text] [Related]
25. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials. Kong L; Zhang Y; Hu C; Guo Y; Lu JJ Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641 [TBL] [Abstract][Full Text] [Related]
26. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy. Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021 [TBL] [Abstract][Full Text] [Related]
27. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort. Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417 [TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related]
29. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis. Su L; Zhang M; Zhang W; Cai C; Hong J Medicine (Baltimore); 2017 Mar; 96(11):e6364. PubMed ID: 28296774 [TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757 [TBL] [Abstract][Full Text] [Related]
31. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma. Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725 [TBL] [Abstract][Full Text] [Related]
33. Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma. Ou D; Wang X; Wu M; Xue F; Li Y; Hu C; He X Strahlenther Onkol; 2020 Mar; 196(3):252-261. PubMed ID: 31701168 [TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA. Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Li Y; Tang QN; Sun XS; Liang YJ; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ J Natl Compr Canc Netw; 2019 Jun; 17(6):703-710. PubMed ID: 31200353 [TBL] [Abstract][Full Text] [Related]
35. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial. Chitapanarux I; Kittichest R; Tungkasamit T; Asakit T; Chomprasert K; Chakrabandhu S; Onchan W; Traisathit P Curr Probl Cancer; 2021 Feb; 45(1):100620. PubMed ID: 32713518 [TBL] [Abstract][Full Text] [Related]
36. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA. Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915 [TBL] [Abstract][Full Text] [Related]
37. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study. Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364 [TBL] [Abstract][Full Text] [Related]
38. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers. Ogul A; Kidi MM; Buyuksimsek M J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108 [TBL] [Abstract][Full Text] [Related]
39. Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Ye L; Oei RW; Kong F; Xu T; Shen C; Wang X; He X; Kong L; Hu C; Ying H Eur Arch Otorhinolaryngol; 2018 May; 275(5):1309-1317. PubMed ID: 29589142 [TBL] [Abstract][Full Text] [Related]
40. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Li PJ; Mo HY; Luo DH; Hu WH; Jin T Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]